更贴近患者！药品集采新规则发布

Core Viewpoint - The newly released rules for the 11th batch of national drug procurement aim to enhance the connection between pharmaceutical companies, hospitals, and patients, promoting a balanced approach to drug supply and industry development [1] Group 1: Drug Supply and Demand Matching - Over 46,000 medical institutions participated in the new round of national drug procurement, with nearly 80% specifying the required brands [2] - The matching degree between drug supply and clinical demand is expected to improve, leading to more stable continuity in clinical medication [3] - Special categories of drugs will see a reduction in the agreed procurement volume from 80% to between 60% and 70% [3] Group 2: Quality Assurance - The new rules raise the quality standards for bidding companies, requiring at least 2 years of production experience for similar dosage forms and compliance with Good Manufacturing Practice (GMP) [4] - Companies with the same bid price will be prioritized based on the volume reported by medical institutions and the absence of significant changes in production processes or raw materials [5] Group 3: Anti-Collusion Measures - The rules address collusion by treating closely related companies as a single entity during bidding and imposing strict penalties for collusion [8] - A "first report leniency" mechanism is introduced to encourage reporting of collusion [8] Group 4: Competition Regulation - New measures are implemented to prevent excessive competition, including setting a price anchor at 50% below the average winning bid for bids that are excessively low [8] - The overall selection rate for this round of procurement remains stable at around 60%, with the potential for an increase due to the new revival rules [8] Group 5: Transparency and Patient Focus - The adjustments were made after extensive consultation, aiming to ensure that patients have access to high-quality and affordable medications [9] - The trend towards greater transparency in drug procurement processes is emphasized, with a focus on returning drug prices to their value and ensuring patient safety [9]